Boxer Capital Management LLC Takes $1.93 Million Position in Definium Therapeutics, Inc. $DFTX

Boxer Capital Management LLC acquired a new position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 163,500 shares of the company’s stock, valued at approximately $1,928,000. Definium Therapeutics comprises approximately 0.6% of Boxer Capital Management LLC’s portfolio, making the stock its 24th biggest holding.

A number of other hedge funds have also modified their holdings of the stock. Stoneridge Investment Partners LLC raised its position in shares of Definium Therapeutics by 7.5% during the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock worth $136,000 after purchasing an additional 804 shares during the period. Cerity Partners LLC boosted its position in shares of Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after purchasing an additional 1,165 shares during the period. Creative Planning increased its stake in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares in the last quarter. Rathbones Group PLC increased its stake in Definium Therapeutics by 7.1% in the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock worth $356,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DFTX has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. HC Wainwright lifted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Wolfe Research initiated coverage on shares of Definium Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $25.00 price target on the stock. Royal Bank Of Canada upped their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, JonesTrading assumed coverage on shares of Definium Therapeutics in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $35.70.

Insider Activity at Definium Therapeutics

In related news, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the completion of the sale, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert Barrow sold 25,791 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares in the company, valued at $10,236,972.55. This trade represents a 3.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 42,667 shares of company stock valued at $561,071. Insiders own 2.26% of the company’s stock.

Definium Therapeutics Trading Up 0.4%

Shares of NASDAQ:DFTX opened at $18.06 on Friday. The firm has a fifty day moving average of $16.58 and a two-hundred day moving average of $13.40. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. Definium Therapeutics, Inc. has a 12-month low of $4.70 and a 12-month high of $19.62. The firm has a market capitalization of $1.78 billion, a P/E ratio of -8.48 and a beta of 2.56.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.